- Report
- March 2024
- 190 Pages
Global
From €3249EUR$3,374USD£2,794GBP
€3610EUR$3,749USD£3,105GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 250 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- February 2024
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- November 2023
- 175 Pages
Global
From €4815EUR$5,000USD£4,141GBP
- Report
- April 2024
- 136 Pages
Global
From €3755EUR$3,899USD£3,229GBP
- Report
- September 2023
- 145 Pages
Global
From €2407EUR$2,499USD£2,070GBP
- Report
- March 2024
- 225 Pages
Global
From €7656EUR$7,950USD£6,584GBP
- Report
- January 2024
- 190 Pages
Global
From €4719EUR$4,900USD£4,058GBP
- Report
- February 2024
- 120 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Report
- February 2024
- 112 Pages
Global
From €4574EUR$4,750USD£3,934GBP
- Clinical Trials
- April 2024
- 220 Pages
Global
From €2408EUR$2,500USD£2,071GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1926EUR$2,000USD£1,656GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
From €1445EUR$1,500USD£1,242GBP
- Report
- November 2023
- 30 Pages
Global
From €2648EUR$2,750USD£2,278GBP
Bevacizumab is a monoclonal antibody used in the treatment of various types of cancer. It is used in combination with other drugs to treat metastatic colorectal cancer, non-small cell lung cancer, glioblastoma, metastatic renal cell carcinoma, and metastatic breast cancer. Bevacizumab works by inhibiting the growth of new blood vessels, which can help slow the growth of tumors. It is administered intravenously and is typically given in combination with other chemotherapy drugs.
Bevacizumab is a widely used drug in the oncology market, and is one of the most prescribed drugs for cancer treatment. It is used in combination with other drugs to treat a variety of cancers, and is often used in combination with chemotherapy. Bevacizumab has been shown to be effective in treating certain types of cancer, and is generally well tolerated.
Some companies in the Bevacizumab market include Genentech, Roche, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more